Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities
Gelteq (GELS) has signed a memorandum of understanding with IDT Australia (ASX: IDT) to establish a dedicated manufacturing facility for its gel-based products. The partnership aims to support the development and scale-up of Gelteq's proprietary gel-based oral delivery platform across pharmaceutical, nutraceutical, and animal health markets.
IDT Australia brings over 50 years of pharmaceutical manufacturing expertise and capabilities in cGMP manufacturing, FDA and TGA approved laboratory testing, and clinical packaging. The agreement includes dedicated facilities, equipment, trained staff, operational support, and necessary regulatory compliance certifications from APVMA, FDA, and TGA.
Gelteq (GELS) ha firmato un memorandum d'intesa con IDT Australia (ASX: IDT) per creare una struttura produttiva dedicata ai suoi prodotti a base di gel. La collaborazione mira a sostenere lo sviluppo e la scalabilità della piattaforma proprietaria di Gelteq per la somministrazione orale di gel, rivolta ai mercati farmaceutico, nutraceutico e della salute animale.
IDT Australia vanta oltre 50 anni di esperienza nella produzione farmaceutica e competenze nella produzione cGMP, test di laboratorio approvati FDA e TGA, e confezionamento clinico. L'accordo prevede strutture dedicate, attrezzature, personale formato, supporto operativo e le necessarie certificazioni di conformità regolatoria da APVMA, FDA e TGA.
Gelteq (GELS) ha firmado un memorando de entendimiento con IDT Australia (ASX: IDT) para establecer una instalación de fabricación dedicada a sus productos a base de gel. La asociación tiene como objetivo apoyar el desarrollo y la ampliación de la plataforma propietaria de Gelteq para la administración oral de geles en los mercados farmacéutico, nutracéutico y de salud animal.
IDT Australia aporta más de 50 años de experiencia en fabricación farmacéutica y capacidades en fabricación cGMP, pruebas de laboratorio aprobadas por FDA y TGA, y envasado clínico. El acuerdo incluye instalaciones dedicadas, equipos, personal capacitado, apoyo operativo y las certificaciones regulatorias necesarias de APVMA, FDA y TGA.
Gelteq (GELS)는 IDT Australia (ASX: IDT)와 양해각서(MOU)를 체결하여 젤 기반 제품 전용 제조 시설을 설립하기로 했습니다. 이 파트너십은 제약, 건강기능식품, 동물 건강 시장 전반에 걸쳐 Gelteq의 독자적인 젤 기반 경구 전달 플랫폼 개발 및 확장을 지원하는 것을 목표로 합니다.
IDT Australia는 50년 이상의 제약 제조 전문성과 cGMP 제조, FDA 및 TGA 승인 실험실 테스트, 임상 포장 능력을 보유하고 있습니다. 이 계약에는 전용 시설, 장비, 숙련된 인력, 운영 지원 및 APVMA, FDA, TGA의 필수 규제 준수 인증이 포함됩니다.
Gelteq (GELS) a signé un protocole d'accord avec IDT Australia (ASX: IDT) pour établir une installation de fabrication dédiée à ses produits à base de gel. Ce partenariat vise à soutenir le développement et la montée en puissance de la plateforme propriétaire de Gelteq pour l'administration orale de gels dans les marchés pharmaceutique, nutraceutique et de la santé animale.
IDT Australia apporte plus de 50 ans d'expertise en fabrication pharmaceutique ainsi que des capacités en fabrication cGMP, tests en laboratoire approuvés par la FDA et la TGA, et conditionnement clinique. L'accord inclut des installations dédiées, des équipements, du personnel formé, un soutien opérationnel et les certifications réglementaires nécessaires délivrées par l'APVMA, la FDA et la TGA.
Gelteq (GELS) hat eine Absichtserklärung mit IDT Australia (ASX: IDT) unterzeichnet, um eine dedizierte Produktionsstätte für seine gelbasierten Produkte einzurichten. Die Partnerschaft zielt darauf ab, die Entwicklung und Skalierung von Gelteqs proprietärer gelbasierter oraler Verabreichungsplattform in den Bereichen Pharma, Nutraceuticals und Tiergesundheit zu unterstützen.
IDT Australia bringt über 50 Jahre Erfahrung in der pharmazeutischen Herstellung sowie Kompetenzen in cGMP-Produktion, FDA- und TGA-zugelassene Labortests und klinische Verpackung mit. Die Vereinbarung umfasst dedizierte Einrichtungen, Ausrüstung, geschultes Personal, operative Unterstützung und die erforderlichen regulatorischen Zertifizierungen von APVMA, FDA und TGA.
- Strategic partnership with established manufacturer IDT Australia with 50+ years of expertise
- Access to FDA and TGA approved facilities and regulatory certifications
- Dedicated purpose-built manufacturing facility for scalable production
- Capability to expand manufacturing capacity to support growth
- Manufacturing facility is still in planning phase, not yet operational
- Agreement is currently a memorandum of understanding, not a final binding contract
Insights
Gelteq secures critical manufacturing infrastructure with IDT Australia, significantly enhancing commercialization capabilities for its gel delivery technology.
This strategic manufacturing agreement between Gelteq and IDT Australia represents a critical infrastructure acquisition for Gelteq's commercialization roadmap. By securing a dedicated, purpose-built manufacturing facility, Gelteq addresses one of the most challenging aspects of pharmaceutical product development - the transition from lab-scale to commercial production.
The partnership provides three essential elements that typically create bottlenecks for innovative delivery technologies: specialized manufacturing facilities with equipment customized for gel production; regulatory compliance infrastructure spanning multiple markets (APVMA, FDA, and TGA certifications); and scalability pathways to accommodate growth without disrupting production.
IDT Australia brings over 50 years of manufacturing expertise and experience with more than 60 market-based drugs, providing Gelteq access to established pharmaceutical development capabilities that would typically require years and significant capital to develop internally. IDT's specialized knowledge in high-containment and high-potency manufacturing suggests the partnership could facilitate development of more complex therapeutic applications for Gelteq's technology.
Most significantly, this agreement potentially accelerates Gelteq's time-to-market across multiple product categories simultaneously, as IDT's regulatory expertise spans pharmaceutical, nutraceutical, and veterinary markets. The partnership structure suggests Gelteq maintains product ownership while leveraging IDT's manufacturing infrastructure - a capital-efficient approach to scaling production capabilities.
Partnership to support the scale-up and commercialization of Gelteq’s proprietary gel-based oral delivery platform
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.
IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs).
“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”
Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”
Highlights of the Agreement:
- Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.
- Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.
- Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.
The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com and our SportsGel brand website www.sportsgel.com.
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
FAQ
What is the partnership between Gelteq (GELS) and IDT Australia?
What regulatory certifications will Gelteq's manufacturing facility have?
What manufacturing capabilities does IDT Australia bring to the Gelteq partnership?
How will the IDT Australia partnership benefit Gelteq's production capabilities?
What markets will Gelteq's manufacturing facility serve?
